In the News

BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET.

A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging, worked together to create this guidance document on the use of somatostatin analogue-based PRRNT. This 120 page guidance document released in February 2013, was compiled taking into account recent literature and experts’ opinion and can be downloaded here. An summary of the guide was also published in the European Journal of Nuclear Medicine and Molecular Imaging.

Over 500 medical professionals attended the 2nd World Congress on Ga68 and Radiotherapy that was held in Chandigarh India, February 28 - March 2, 2013.  Over the course of 3 days over 100 presentations and posters were presented reflecting the current usage of Ga68 and PRRT around the world as well as new and exciting development that have taken place since the 1st world congress in 2011.  The abstracts for this conference as well as for the 22nd Singapore Nuclear Review are available free of charge at the World Journal of Nuclear Medicine.  

This congress saw advancement in using GA68 as a tracer for infection and inflammation as well as for receptor positive forms of breast and prostate cancer in addition to its use as a

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open in the US and Europe and is actively recruiting patients.

The study is seeking 200 patients at over 50 institutions in a randomized trial - those that are randomized to the non-PRRT arm will receive LAR 60 (high dose).

To learn more about the trial, please visit clinicaltrials.gov.

For the third year, the Society of Nuclear Medicine and Molecular Imaging's Patient Advocacy Advisory Board developed a Patient Program to address key topics of interest to the patient and patient advocacy community.  These presentations were given at the SNMMI Patient Education Day, June 9th in Vancouver, BC.

While we were in Chandigarh, India for the 2nd World Congress on Ga68 we were abole to film the following press conference with Professors Baum, Shultz and Singh about the importance of the Congress. Please make sure to click the read more button to see all 3 talks.